2023-04-19 09:14:13 ET
- Enlivex Therapeutics ( NASDAQ: ENLV ) said that the U.S. Patent and Trademark Office issued a notice of allowance for a patent application covering methods of using Allocetra in combination with chimeric antigen receptor (CAR) T-cell therapy to treat tumors.
- The company expects the patent, application no. 16/076,026, will be issued in this year and provide intellectual property protection through at least 2036.
- Allocetra is being developed as a universal, off-the-shelf cell therapy aimed to reprogram macrophages into their homeostatic state, according to Enlivex.
- ENLV +8.28% to $3.14 premarket April 19
For further details see:
Enlivex stock soars on upcoming US patent linked to cell therapy Allocetra